China Beijing Tong Ren Tang (Group) Co., Ltd.

The Tong Ren Tang brand was founded in 1669 (the 8th year of the Kangxi reign in the Qing Dynasty). Since 1723 (the 1st year of the Yongzheng reign in the Qing Dynasty), it supplied imperial medicines to the Qing court, serving eight emperors over 188 years. The founding of the People's Republic of China in 1949 gave Tong Ren Tang, which had weathered many vicissitudes, a new lease of life. In 1992, China Beijing Tong Ren Tang Group Corporation was established, and in 2001 it was restructured into a wholly state-owned company, with a modern corporate system gradually established and improved within the Group. In 1997, its subsidiary Tong Ren Tang Co., Ltd. was listed on the Shanghai Stock Exchange; in 2000, Tong Ren Tang Technologies Co., Ltd. was listed on the Hong Kong Stock Exchange; and in 2013, Tong Ren Tang International Co., Ltd. was listed on the Hong Kong Stock Exchange, bringing the Group's overall strength to a new level. In 2019, the Group fully implemented the Party Central Committee's decisions and deployments for developing traditional Chinese medicine (TCM), focused on the "Two Centenary Goals", formulated strategic thinking for the Group's development in the new era, and commissioned third-party professional institutions for strategic consulting, embarking on a new journey toward high-quality development. The Group adheres to TCM as its main focus. Currently, its business structure has formed five major sectors with the pharmaceutical industry as the core, supported by health and wellness, medical elderly care, commercial retail, and international pharmaceuticals, building a comprehensive TCM health industry chain integrating planting (breeding), manufacturing, sales, medical care, wellness, and R&D. Marked by the establishment of a production base in Hong Kong by Tong Ren Tang International Group, the Group has achieved a leap from "Beijing's Tong Ren Tang" and "China's Tong Ren Tang" to "the world's Tong Ren Tang". It has now set up business and service terminals in 28 countries and regions across five continents, accelerating the internationalization of TCM. It owns seven sub-groups, two institutes, and several directly affiliated subsidiaries, with over 2,400 retail terminals and medical institutions providing year-round health services to consumers. It has 36 production bases and over 110 modern production lines, capable of producing over 2,600 kinds of medicines and health foods in six major categories and more than 20 dosage forms. Famous medicines such as Angong Niuhuang Wan, Tongren Niuhuang Qingxin Wan, and Tongren Wuji Baifeng Wan are household names. It has one national engineering center and a post-doctoral research workstation, with a sound scientific research and development system. Since the 13th Five-Year Plan period alone, it has completed R&D of 265 new products; Bajitian Oligosaccharide Capsules, which won the Beijing Municipal Science and Technology First Prize, filled a gap in TCM treatment of depression. The Group insists on innovative processes and technologies to solve common technical problems in the industry, completely changing the outdated manual operation in TCM production. In 2018, its total operating revenue reached 19 billion yuan, total profits 2.7 billion yuan, and total assets exceeded 29 billion yuan. Since the Group's establishment in 1992, it has accumulated 36.5 billion yuan in taxes and profits, achieving value preservation and appreciation of state-owned assets. It has successively won honors such as the "China Trademark Award - Trademark Utilization Award", the "Madrid International Trademark Registration Special Award", the "First Beijing Municipal People's Government Quality Management Award", and the "Pharmaceutical Industry Backbone Enterprise Award for the 70th Anniversary of the Founding of the People's Republic of China". As one of the first batch of China Time-honored Brands, the Group insists on the path of coordinated development as an economic entity and cultural carrier, earnestly fulfilling its economic, political, social, and cultural heritage responsibilities as a state-owned enterprise, and playing a unique role in promoting TCM development and inheriting TCM culture. "Cultivating virtue and healing lives" is the original aspiration of Tong Ren Tang, and "wholeheartedly serving people's health" is its unchanging purpose. Tong Ren Tang has internalized ancient maxims such as "No one sees the making, but heaven knows the heart", "No matter how complex the processing, labor must never be spared; no matter how precious the ingredients, quality must never be compromised", and "May the world be free of disease, even if our medicines gather dust" into its corporate code of conduct, giving rise to its pharmaceutical characteristics of "unique formulas, superior ingredients, exquisite craftsmanship, and remarkable efficacy", and laying the foundation of its quality and integrity culture. It adheres to craftsmanship, inheriting and innovating, passing the torch from generation to generation. The Group possesses three national intangible cultural heritage items (Tong Ren Tang TCM culture, traditional TCM processing techniques, and Angong Niuhuang Wan production skills) along with a number of municipal and district-level "intangible heritage" projects. It has 37 representative inheritors at the national, municipal, and district levels, 41 Tong Ren Tang TCM masters, 8 TCM masters, and 20 special skills inheritance masters. Through deepening education on socialist core values, implementing the "Four Bands and Four Promotions" party building innovation and cultural inheritance initiative, and advancing dual assessments of party building and operations, it has promoted the enterprise spirit of cherishing the brand, united struggle, entrepreneurial dedication, and the pursuit of excellence, injecting new impetus into corporate development.